Elizabeth Jungman

Elizabeth served as Chief of Staff to the FDA Commissioner where she oversaw the day-to-day management of the agency and provided strategic counsel to agency leadership. Prior to that role, Elizabeth led policy for FDA's Center for Drug Evaluation and Research (CDER) where she was the Associate Director for Policy and Director of CDER's Office of Regulatory Policy (ORP). In these roles Elizabeth advised the Director and other senior officials on drug policy development, implementation, and long-range program strategy. She helped oversee the development of regulations, policies, and procedures affecting nearly every aspect of CDER.

Before joining CDER, Elizabeth was the Director of Public Health Programs at the Pew Charitable Trusts. She has also served as Senior Health Policy Adviser with the U.S. Senate Committee on Health, Education, Labor, and Pensions, where she was the Senate lead in drafting and negotiating the FDA Safety and Innovation Act of 2012 and other health- and drug-related legislation, including, pandemic preparedness, drug compounding, and supply chain security. Her deep understanding of regulatory frameworks—combined with her operational knowledge of both the FDA and Capitol Hill sets Elizabeth apart when clients are navigating complex drug policy and compliance issues.

Elizabeth earned her bachelor's degree in biology from Harvard College, law degree from Georgetown University, and has a master's degree in public health from Johns Hopkins.